These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21038080)

  • 41. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
    Sagong M; Lim S; Chang W
    Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
    Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
    Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Focal macular electroretinograms after intravitreal injections of bevacizumab for age-related macular degeneration.
    Iwata E; Ueno S; Ishikawa K; Ito Y; Uetani R; Piao CH; Kondo M; Terasaki H
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4185-90. PubMed ID: 22618591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
    Kang HM; Koh HJ
    Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis.
    Cionni DA; Lewis SA; Petersen MR; Foster RE; Riemann CD; Sisk RA; Hutchins RK; Miller DM
    Ophthalmology; 2012 Feb; 119(2):327-32. PubMed ID: 22133795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
    Weigert G; Michels S; Sacu S; Varga A; Prager F; Geitzenauer W; Schmidt-Erfurth U
    Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
    Kang HM; Koh HJ; Lee CS; Lee SC
    Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal bevacizumab for age-related macular degeneration with good visual acuity.
    Takahashi M; Sato T; Kishi S
    Jpn J Ophthalmol; 2010 Nov; 54(6):565-70. PubMed ID: 21191717
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
    Retina; 2006; 26(9):994-8. PubMed ID: 17151485
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up.
    Costagliola C; Semeraro F; Cipollone U; Rinaldi M; della Corte M; Romano MR
    Graefes Arch Clin Exp Ophthalmol; 2009 Aug; 247(8):1031-7. PubMed ID: 19404665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.
    Kim SJ; Yu HG
    Retina; 2011 Oct; 31(9):1827-34. PubMed ID: 21734621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy.
    Kim KS; Lee WK
    Jpn J Ophthalmol; 2011 Jul; 55(4):370-377. PubMed ID: 21647565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined therapy: photodynamic therapy and bevacizumab to treat myopic neovascular membranes. One-year follow-up.
    Desco MC; Mataix J; Garcia-Pous M; Palacios-Pozo E; Navea A
    Retina; 2011 Mar; 31(3):475-81. PubMed ID: 20966825
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy.
    Iriyama A; Obata R; Inoue Y; Takahashi H; Tamaki Y; Yanagi Y
    Graefes Arch Clin Exp Ophthalmol; 2008 Mar; 246(3):339-44. PubMed ID: 17805556
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination therapy in exudative age-related macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab.
    Wan MJ; Hooper PL; Sheidow TG
    Can J Ophthalmol; 2010 Aug; 45(4):375-80. PubMed ID: 20648087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation.
    Rouvas AA; Papakostas TD; Ladas ID; Vergados I
    Graefes Arch Clin Exp Ophthalmol; 2008 Feb; 246(2):315-8. PubMed ID: 17957379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks: a long-term follow-up study.
    Rosina C; Romano M; Cigada M; de Polo L; Staurenghi G; Bottoni F
    Eur J Ophthalmol; 2015; 25(1):47-50. PubMed ID: 25044143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.